Presence of Cofactor NADPH Slows Down the Dissociation of Methotrexate from Dihydrofolate Reductase from Bacillus stearothermophilus

Ryan Seamus Foley
Montclair State University

Follow this and additional works at: https://digitalcommons.montclair.edu/etd

Part of the Chemistry Commons

Recommended Citation
https://digitalcommons.montclair.edu/etd/102

This Thesis is brought to you for free and open access by Montclair State University Digital Commons. It has been accepted for inclusion in Theses, Dissertations and Culminating Projects by an authorized administrator of Montclair State University Digital Commons. For more information, please contact digitalcommons@montclair.edu.
The goal of this project was to study the effect of the presence or absence of the cofactor NADPH on the binding and release of ligand methotrexate (MTX) to/from *Bacillus stearothermophilus* (*Bs*) dihydrofolate reductase (DHFR). A previously developed, fluorescently-labeled *Bs* DHFR (C73A/S131CMDCC DHFR) was used to investigate the kinetics and protein conformational motions associated with the binding of NADPH and the binding of methotrexate to the holoenzyme. This *Bs* DHFR contains a distal cysteine where the fluorophore, N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-carboxamide (MDCC) can be covalently attached. This probe is sensitive to the local molecular environment, reporting on changes in the protein conformation associated with ligand binding. Intrinsic tryptophan fluorescence of the unlabeled *Bs* DHFR construct (C73A/S131C DHFR) was also used to detect changes in conformational motion upon ligand and cofactor association and dissociation.

Previous stopped-flow data indicates the presence of two native state *Bs* DHFR conformers that bind to ligand at different rates. Similarly, two conformations of *Escherichia coli* DHFR in unbound state were reported. Intrinsic tryptophan fluorescence of C73A/S131C *Bs* DHFR and probe fluorescence of C73A/S131CMDCC *Bs* DHFR both report on ligand binding. The labeled and unlabeled DHFRs report on the two different conformers, respectively. This study shows that NADPH binding significantly slows down the dissociation rate (approx. 1000-fold) of methotrexate from *Bs* DHFR from $0.015 \pm 0.007965 \text{ s}^{-1}$ to $0.000021 \pm 0.00000271 \text{ s}^{-1}$. This demonstrates the importance of NADPH in the analysis and study of DHFR.
MONTCLAIR STATE UNIVERSITY

PRESENCE OF COFACTOR NADPH SLOWS DOWN THE DISSOCIATION OF METHOTREXATE FROM DIHYDROFOLATE REDUCTASE FROM BACILLUS STEAROTHERMOPHILUS

By

Ryan S. Foley

A Master’s Thesis Submitted to the Faculty of Montclair State University

In Partial Fulfillment of the Requirements For the Degree of

MASTER OF SCIENCE

January 2018

College of Science and Mathematics

Department Chemistry and Biochemistry

Thesis Committee:

Dr. Nina M. Goodey

Dr. John Siekierka

Dr. David Talaga

Thesis Sponsor
Committee Member
Committee Member
PRESENCE OF COFACTOR NADPH SLOWS DOWN THE DISSOCIATION OF
METHOTREXATE FROM DIHYDROFOLATE REDUCTASE FROM BACILLUS
STEAROTHERMOPHILUS

A THESIS

Submitted in partial fulfillment of the requirements
For the degree of Master of Science

by
RYAN SEAMUS FOLEY
Montclair State University
Montclair, NJ
2018
Table of Contents:

Abstract
Thesis signature page
Title page
Table of contents
List of figures

1. Introduction

2. Material and methods
   a. Protein expression and purification
   b. Preparation of C73A/S131CMDCC Bs DHFR
   c. Unlabeled apoenzyme Bs DHFR mixed with methotrexate
   d. Labeled apoenzyme Bs DHFR mixed with methotrexate
   e. Unlabeled apoenzyme Bs DHFR mixed with NADPH
   f. Labeled apoenzyme Bs DHFR mixed with NADPH
   g. Unlabeled holoenzyme Bs DHFR mixed with methotrexate
   h. Labeled holoenzyme Bs DHFR mixed with methotrexate
   i. Data Analysis
3. Results and discussion

a. Methotrexate Mixed with Bs DHFR 16
b. NADPH Mixed with Bs DHFR 21
c. Methotrexate mixed with DHFR/NADPH Holoenzyme 26
d. Dissociation rates of methotrexate from Bs DHFR and the DHFR:NADPH complex 29
e. Discussion 32

4. References 34

5. Appendix 37

6. Inventory 39
List of Figures:

Figure 1: Visualization enzyme conformers 1
Figure 2: Reaction of Dihydrofolate to Tetrahydrofolate 2
Figure 3: The structure of Bs DHFR 5
Figure 4: Growth and purification process 6
Figure 5: Gel for the purification of C73A/S131C Bs DHFR 7
Figure 6: Calculation of enzyme concentration 8
Figure 7: Minimal model for methotrexate binding 14
Figure 8: Initial estimates for binding constants 15
Table 1: Dynafit control response values 16
Figure 9: Bs DHFR binding with methotrexate: Model 18
Figure 10: Bs DHFR binding with methotrexate: Graphs 19
Table 2: Bs DHFR binding with methotrexate: Data 20
Figure 11: Bs DHFR conformational change following MTX binding: Graphs 21
Figure 12: Bs DHFR binding with NADPH: Graphs 22
Figure 13: Bs DHFR conformational change following NADPH binding: Graphs 24
Figure 14: Bs DHFR binding with NADPH: Model 25
Table 3: Bs DHFR binding with NADPH: Data 25
Figure 15: Bs DHFR.NADPH binding with methotrexate: Graphs 27
Figure 16: Bs DHFR.NADPH binding with methotrexate: Model 28
Table 4: Bs DHFR.NADPH binding with methotrexate: Data 28
Figure 17: Bs DHFR dissociation from methotrexate: Graphs 30
Figure 18: Bs DHFR.NADPH dissociation from methotrexate: Graphs 31
Figure 19: Labeled dissociation comparison 33
Figure 20: Calculation equations of absorbance and labeling efficiency 37
Figure 21: Sample calculation sheet of absorbance 38
Introduction:

Dihydrofolate reductase (DHFR) is an essential enzyme found in nearly all life forms. DHFR catalyzes the formation of tetrahydrofolate from dihydrofolate using the cofactor NADPH as the reducing agent. Tetrahydrofolate is required in the synthesis of purines, thymidylate and several amino acids and reducing its activity prevents cells from growing or multiplying. This makes DHFR an important pharmaceutical target for development of antibiotics and pharmaceuticals targeting cancer [41, 42]. Pharmaceuticals that inhibit DHFR’s function are known as antifolates [19]. Studying how these drugs interact with DHFR is important for further research into protein dynamics and the design of new pharmaceuticals.

DHFR has become one of the main model systems for studying protein conformational motions [10]. Enzymes are thought to exist in a variety of conformations that are in equilibrium with each other. For many enzymes, one conformer is the stable state; for others, more than one stable conformer exists in equilibrium [13, 27]. An enzyme that exists in multiple stable conformers has the possibility of more elaborate regulation. Studies on how one conformer as opposed to the other binds ligands leads to a better understanding of potential regulation [1, 8, 9, 24].

Figure 1: A visualization of how enzyme conformers exist in many conformations with a prominent few conformations that are most stable.
Figure 2: The reaction of Dihydrofolate to Tetrahydrofolate by Dihydrofolate Reductase using NADPH as a cofactor.
Previous published work on DHFR has demonstrated at least two stable conformations that bind ligands at different rates \[30\]. A confounding factor of this system is the cofactor NADPH. Most research has focused on the apoenzyme (enzyme without cofactor bound), presumably to avoid the complexity of the bound cofactor. As a result, less is known about the binding of methotrexate (MTX) to the holoenzyme (enzyme with cofactor bound). However, the holoenzyme needs to be studied because it is the biologically relevant species. Understanding the interactions between DHFR, NADPH, and methotrexate will increase the understanding of structure function relationships in DHFR. Thus, the goal is to determine the extent to which NADPH impacts the binding of DHFR to methotrexate and the associated conformational dynamics. There are three specific goals:

- Find rates of binding and dissociation and associated conformational changes of methotrexate binding to \textit{B}s DHFR.
- Determine the rates of binding and dissociation of NADPH to/from \textit{B}s DHFR and rates of associated conformational changes.
- Determine the rate of methotrexate binding to the \textit{B}s DHFR holoenzyme (with NADPH bound), rate of release of methotrexate from holoenzyme, and rates of associated conformational changes.

Stopped-flow fluorescence spectroscopy was used to determine rates of binding, dissociation and associated conformational changes. This method measures changes in fluorescence intensity over time after two fluid flows are mixed together. The measurement begins as the flows are stopped. The dead time of the instrument is approximately one to two milliseconds. In this project, I measured changes in the
intensity of the intrinsic tryptophan fluorescence for the unlabeled enzyme. I measured changes in the fluorescence intensity of the covalently bound fluorophore MDCC for the labeled enzyme. In both measurements, the intensity of the fluorophore signal will change when the conformation of the Bs DHFR changes. This is because the environment of the fluorophore changes when the protein undergoes a conformational change.

Integrating these two fluorescence signals allowed me to differentiate between binding events associated with each conformer. Each of the two conformers may have different binding mechanisms to methotrexate. For example, one conformer may bind faster than the other or release methotrexate more rapidly. There may also be conformational changes that are associated with the methotrexate binding event or ones that follow the binding event for one or both conformers. At low methotrexate concentrations, concentration dependent binding steps can be seen the best. At higher methotrexate concentrations, the concentration dependent binding steps are so fast they are over in the dead time of the instrument, allowing the slower concentration independent conformational changes to be measured clearly. With these tools, we determined the rates of binding events and conformational changes for the binding of NADPH and methotrexate to both the apoenzyme, the enzyme without its cofactor NADPH, and the holoenzyme, the enzyme with the cofactor NADPH bound.
**Figure 3:** A graphical representation of the structure of *Bs* DHFR (PDB ID: 1ZDR) [1]. These models show the front (top) where the MTX binding site is located and the back (bottom) where the MDCC fluorescent probe gets attached. Residue 131, the site of labeling, is shown as a magenta sphere.

**Material and methods**

**Protein expression and purification**

An *E. coli* BL21 cell line transformed with C73A S131C *Bs* DHFR with the was obtained from a previous study done by Maryam Alapa [1]. The unlabeled *Bs* DHFR construct (C73A/S131C *Bs* DHFR) was grown and expressed in LB broth containing 100 μg/mL ampicillin at 37 °C. OD₆₀₀ was allowed to reach 0.6; expression was then induced using 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and the cells expressed overnight at 30 °C. Cells were washed in 0.9% NaCl and pelleted.
Figure 4: Process figure for the growth and purification of C73A S131C Bs DHFR.

The cells were suspended in 40 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) buffer at pH 6.8, then lysed by sonication at 10% duty with an output of 5 pulsed for 4 minutes. The supernatant was loaded onto an SP-sepharose C-25 column and eluted with 0.2 M NaCl in 40 mM HEPES (pH 6.8). The Bs DHFR fractions were collected, exchanged into 40 mM HEPES (pH 6.8), concentrated, and stored at -80 °C with a typical yield of 2.5 mg of protein for 1 L of Expressed protein broth. The purity was verified by SDS-PAGE electrophoresis.
**Figure 5:** This is a typical gel for the purification of C73A/S131C *Bs* DHFR using a SP-sepharose C-25 column. The molecular weight of *Bs* DHFR is 18.6 kDa A) lysate, B) flow column 1, C) flow column 2, D) eluted DHFR 1, E) eluted DHFR 2, F) concentrated DHFR (approximately 0.002 mg) at very high purity.

*Preparation of C73A/S131CMDCC Bs DHFR*

Covalent attachment of the MDCC fluorophore to cysteine on the *Bs* DHFR complex at position 131 was initiated by adding a 3-fold molar excess of 0.22 mM stock solution of MDCC fluorophore (ThermoFisher Scientific, Catalog number: D10253, 7-Diethylamino-3-(((2-Maleimidyl)ethyl)amino)carbonyl)coumarin, MW 383.4 g/mol), dissolved in dimethyl sulfoxide, to purified C73A/S131C *Bs* DHFR in pH 7.2 HEPES buffer. The final concentrations were 139.1 μM of MDCC and 41.5 μM of *Bs* DHFR with
a final volume of 1.65 mL. The mixture was covered with aluminum foil to protect the sample from light and incubated at room temperature for 2 h. The sample was dialyzed twice, once for 4 h at 4 °C and once overnight at 4 °C in HEPES pH 6.8 to remove excess dye and to exchange buffer. The extinction coefficient of DHFR (25,565 M⁻¹cm⁻¹ at 280 nm) and of MDCC (10,000 M⁻¹cm⁻¹ at 280 nm and 50,000 M⁻¹cm⁻¹ at 419 nm) were used to calculate labeling efficiency. Labeling efficiency was found to be ~99.4 % from absorbance measurements at 280 and 419 nm using a Thermo Scientific NanoDrop 2000c UV-Vis spectrophotometer.

<table>
<thead>
<tr>
<th></th>
<th>Absorption</th>
</tr>
</thead>
<tbody>
<tr>
<td>A280 DHFR</td>
<td>25565</td>
</tr>
<tr>
<td>A280 MDCC</td>
<td>10000</td>
</tr>
<tr>
<td>A419 MDCC</td>
<td>50000</td>
</tr>
</tbody>
</table>

**Figure 6:** This shows the equation and constants used in the calculation of enzyme concentration, amount of MDCC needed for the labeling, and the labeling efficiency. Labeling efficiency is calculated by comparing the concentration calculation of MDCC at 419 nm to the concentration calculation of DHFR at 280nm (subtracting out the A280 of MDCC from the total). Sample calculation Fig. 19 in Appendix.

Unlabeled apoenzyme Bs DHFR mixed with methotrexate

Methotrexate (2–200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR in 50 mM 2-(N-morpholino) ethanesulfonic acid, 25 mM tris(hydroxymethyl)-aminomethane, 25 mM ethanolamine, and 100 mM NaCl (MTEN buffer) at pH 7 in an Applied Photophysics SX20 stopped-flow apparatus. The changes in fluorescence emission
intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25 – 500 s. Five individual traces were used to obtain an average trace for each condition. Control data for responses were obtained by taking fluorescence readings of each component when separately when combined in the stopped-flow apparatus with buffer. For example, to determine the contribution of DHFR to the fluorescence of the DHFR/MTX experiment, DHFR was mixed in the stopped-flow cell with buffer and the fluorescence measured.

To measure the dissociation rate of the DHFR-MTX complex, 2 μM enzyme was incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM trimethoprim (TMP) which displaces methotrexate in the active site. The dissociation event was monitored by following the fluorescence emission changes at 320 nm for 500s.

To further explore the dissociation rate of the DHFR-MTX complex a concentration of 1 μM enzyme, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence readings) and placed in a Fluoromax SX20 spectrophotometer. The dissociation event was monitored by following the fluorescence emission changes at 320 nm for 600s and 172800s (48h).

*Labeled apoenzyme Bs DHFR mixed with methotrexate*

Methotrexate (2–200 μM) was mixed with 2 μM of C73A/S131C MDCC Bs DHFR in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence
emission intensity for C73A/S131C<sub>MDCC</sub> (excitation at 419 nm, emission with a 450 nm cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an average trace for each condition. Control data for responses were obtained by taking fluorescence readings of each component separately when combined in the stopped-flow apparatus with buffer.

To measure the dissociation rate of the DHFR-MTX complex, 2 μM enzyme was incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation event was monitored by following the fluorescence emission changes at 450 nm for 500s.

To further explore the dissociation rate of the DHFR-MTX complex a concentration of 1 μM enzyme, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence readings) and placed in a Fluoromax SX20 spectrophotometer. The dissociation event was monitored by following the fluorescence emission changes at 450 nm for 600s and 172800s (48h)

Unlabeled apoenzyme Bs DHFR mixed with NADPH

NADPH (2–200 μM) was mixed with 2 μM of C73A/S131C Bs DHFR in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence emission intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an average trace for each condition.
Control data for responses were obtained by taking fluorescence readings of each component separately when combined in the stopped-flow apparatus with buffer.

Labeled apoenzyme Bs DHFR mixed with NADPH

NADPH (2–200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence emission intensity for C73A/S131CMDCC (excitation at 419 nm emission with a 450 nm cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an average trace for each condition. Control data for responses were obtained by taking fluorescence readings of each component separately when combined in the stopped-flow apparatus with buffer.

Unlabeled holoenzyme Bs DHFR mixed with methotrexate

Methotrexate (2–200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR, pre-incubated with 10 µM NADPH, in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence emission intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an average trace for each condition. Control data for responses were obtained by taking fluorescence readings of each component separately when combined in the stopped-flow apparatus with buffer.

To measure the dissociation rate of the DHFR-NADPH-MTX complex, 2 µM enzyme incubated with 10 µM NADPH was incubated with 10 µM methotrexate in
MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation event was monitored by following the fluorescence emission changes at 320 nm for 500s.

To further explore the dissociation rate of the DHFR-NADPH-MTX complex a concentration of 1 μM enzyme, 5 μM NADPH, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence readings) and placed in a Fluoromax SX20 spectrophotometer. The dissociation event was monitored by following the fluorescence emission changes at 320 nm for 600s and 172800s (48h)

*Labeled holoenzyme Bs DHFR mixed with methotrexate*

Methotrexate (2–200 μM) was mixed with 2 μM of C73A/S131C<sub>MDCC</sub> Bs DHFR pre-incubated with 10 μM NADPH in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence emission intensity C73A/S131C<sub>MDCC</sub> (excitation at 419 nm, emission with a 450 nm cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an average trace for each condition. Control data for responses were obtained by taking fluorescence readings of each component separately when combined in the stopped-flow apparatus with buffer.

To measure the dissociation rate of the DHFR-NADPH-MTX complex, 2 μM enzyme incubated with 10 μM NADPH was incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-
flow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation event was monitored by following the fluorescence emission changes at 450 nm for 500s.

To further explore the dissociation rate of the DHFR-NADPH-MTX complex a concentration of 1 μM enzyme, 5 μM NADPH, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence readings) and placed in a Fluoromax SX20 spectrophotometer. The dissociation event was monitored by following the fluorescence emission changes at 450 nm for 600s and 172800s (48h)

Data Analysis

Data Analysis was done using Dynafit 4 [23], a minimization fitting program, to do an optimization analysis to fit the data to the following kinetic model. The model for the binding of methotrexate to Bs DHFR elucidated by previous studies (Fig. 4) was used as a basis for the Dynafit analysis. For each section of the model, only one, two steps, or pure conformational change step (E+L→E.L, or E’+L→E’.L→E.L or E’.L →E.L) were used with the goal of using as few steps as possible to adequately explain each set of the data. Each trace typically shows evidence of only one or two steps with all timescales and wavelength showing the whole picture. Dynafit files and scripts are found in each respective binding folder under the file heading: Dynafit Ready Data Files + Scripts. Binding (k1) steps were all successfully fit to a one step model and all conformational change (k2) steps were fit to a simple conformational change step as well as a two step model.
Figure 7: The minimal model for methotrexate binding to Bs DHFR. E and E’ represent different conformational states of Bs DHFR, L represents a ligand (Methotrexate or NADPH in this case), and E.L and E’.L represent different conformational states of Bs DHFR bound to a ligand. The rate constants are first order rate constants in units of s\(^{-1}\) for the conformational changes and second order rate constant μM\(^{-1}\) s\(^{-1}\) for the ligand binding steps.

Analysis for the data was carried out through an iterative process. Initial estimates for parameters such as enzyme, buffer, and ligand responses (Table 1) were determined from control data. Responses were determined by subtracting out the background fluorescence and dividing by concentration. The control parameters were constantly monitored to prevent significant deviation from measured values. These parameters included the response values for the enzyme alone, the response values for the ligand alone, and the offset which corresponds to the response generated by the buffer alone. Based on rough single exponential analysis of the emission vs. time curves, using multiple concentrations of methotrexate and NADPH mixed with the enzyme, initial parameter estimates for \(k_1\) along with the rough values for the known responses were used to get an initial calculation for the concentration of enzyme (Fig. 8).
Figure 8: Initial estimates for binding constants. The estimate of the binding constant is indicated by the slope of a best fit linear line through the data (red box). Only the approximation of L MTX W.NADPH was quite far off in terms of precision. This data as well as the calculation of the kObs values for each concentration can be found in Folder: kObs graphs and data, within each of the corresponding binding folders.
This concentration reflects the percent of the enzyme that is in the E conformation for binding NADPH through the E+L→EL pathway. This is important for knowing the distribution between E and E’ while the total enzyme concentration is known to be 1 μM. With nearly all parameters decently defined, each trace was run through an iterative process where the parameters were allowed to vary individually and in groups as well as all at once to develop a best fit trace for each fitting. The values from these were then used to determine global best fits across data sets.

<table>
<thead>
<tr>
<th></th>
<th>NADPH</th>
<th>Binding</th>
<th></th>
<th>MTX</th>
<th>Binding</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>L</td>
<td>U</td>
<td></td>
<td>L</td>
<td>U</td>
</tr>
<tr>
<td>DHFR</td>
<td>1.92</td>
<td>0.477</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NADPH</td>
<td>0.000001</td>
<td>0.0352</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHFR.NADPH</td>
<td>0.965</td>
<td>0.961</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHFR’.NADPH</td>
<td>0.942</td>
<td>0.94</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DHFR</td>
<td>1.935</td>
<td>0.86</td>
<td>DHFR.NADPH</td>
<td>5.21</td>
<td>0.89</td>
</tr>
<tr>
<td>MTX</td>
<td>0.00001</td>
<td>0.001</td>
<td>MTX</td>
<td>0.00001</td>
<td>0.001</td>
</tr>
<tr>
<td>DHFR.MTX</td>
<td>0.934</td>
<td>0.756</td>
<td>DHFR.NADPH.MTX</td>
<td>5.1</td>
<td>0.856</td>
</tr>
<tr>
<td>DHFR’.MTX</td>
<td>0.746</td>
<td>0.73</td>
<td>DHFR’.NADPH.MTX</td>
<td>5.1</td>
<td>0.83</td>
</tr>
</tbody>
</table>

**Table 1**: Control values for the Dynafit response constants. Used as initial values and refined through the Dynafit iterative modeling process. **File**: Response Values.

**Results and Discussion**

* METHOTREXATE MIXED WITH BS DHFR*

Independently confirming the model of methotrexate binding and the rates at which methotrexate binds to *Bs DHFR* is important for further analysis. Knowing the rates of binding and conformational changes and how they are different for the
DHFR-NADPH system is important for determining NADPH’s role in methotrexate binding. Seeing the same previously observed conformational changes researched by Maryam Alapa would ideally confirm the conformational equilibrium in Bs DHFR [1].

The binding of methotrexate to unlabeled Bs DHFR causes a change in tryptophan fluorescence (290 nm) intensity. There are three tryptophan molecules (Trp22, Trp85 and Trp135) in our Bs DHFR enzyme, one of which is in the active site. These tryptophan molecules give off varying amounts of fluorescence depending on their local environment. For instance, one can clearly detect change in the fluorescence intensity when a molecule is binding to the active site and detect changes in fluorescence intensity as the protein shifts conformation [1].

The binding of methotrexate to unlabeled Bs DHFR causes a fast methotrexate concentration dependent decrease in tryptophan (290) fluorescence intensity. There is also a second, slower decrease in fluorescence, the rate of which does not vary with methotrexate concentration. The traces were fitted to a two-step equation. The fast concentration dependent decrease is over within 0.25 seconds and has a $k_1$ of 23.8 ± 2.2 μM$^{-1}$s$^{-1}$ and $k_1$ was calculated to be 0.8 ± 0.29 s$^{-1}$. (Table 2) The fast step is attributed to methotrexate binding, $k_1$, and the slower step is attributed to the conformational change, $k_2$, as the DHFR-MTX complex moves to equilibrium between its two forms. The rate constant $k_2$ was found to be 0.02 ± 0.0027 s$^{-1}$. (Table 2) It was not possible to determine $k_2$ from this particular data.

The binding of methotrexate to labeled Bs DHFR causes a slower concentration dependent decrease in MDCC fluorescence (419 nm) intensity. The MDCC probe which is attached to the Bs DHFR at a distal site is sensitive to small changes in its local
environment changing fluorescence intensity as any binding or conformational changes occur. The traces were fitted to a two-step equation. This is a concentration dependent decrease is over within 100 seconds and has a $k_4$ of $0.072 \pm 0.00013 \, \text{μM}^{-1}\text{s}^{-1}$ and a $k_4$ of approximately $0.0064 \pm 0.000066 \, \text{s}^{-1}$. (Table 2)

Longer unlabeled traces showed a slow decrease in fluorescence intensity indicating a slow methotrexate concentration independent decrease. By running these samples at high methotrexate concentrations, the methotrexate concentration dependent step becomes so fast that it cannot be observed on the timescale of our data collection and all that can be seen is the concentration independent step. These longer traces were fit to a two-step model. The fast step is attributed to methotrexate binding ($k_1$), and the slower step is attributed to the conformational change ($k_2$) as the DHFR-MTX complex shifts its conformation finding a new conformation equilibrium with different amounts of DHFR being in each conformation. The rate constant $k_2$ was found to be $0.02 \pm 0.0027 \, \text{s}^{-1}$ and $k_2$ could not be calculated from the data. (Table 2)

![Figure 9: Model for the rates of binding and conformational changes associated with methotrexate binding to the unlabeled Bs DHFR and labeled Bs DHFR.](image_url)
**Figure 10:** Unlabeled *B. s* DHFR (1 μM) mixed with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (left). **Data File:** U MTX Binding No.NADPH 0.25s Data. **Data Folder:** U MTX Binding No.NADPH. This shows a fast concentration dependent fluorescence decrease corresponding to the $k_1$ step of rate 23.8 ±2.2 μM⁻¹s⁻¹.

Labeled *B. s* DHFR (1 μM) mixed with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (right). **Data File:** L MTX Binding No.NADPH 100s Data. **Data Folder:** L MTX Binding No.NADPH. This shows a much slower concentration dependent fluorescence decrease corresponding to the $k_4$ step of rate 0.072 ±00013 μM⁻¹s⁻¹. These analyses were done in Dynafit and the script files are located in the Dynafit Ready Data Files + Scripts folder within each relevant binding folder. These very different rates at two distinct timescales that are both concentration dependent is what indicates that there are two separate conformers binding at separate rates. This pattern was previously determined in prior research by Maryam Alapa [ 1 ]. Maryam Apala’s research yielded two $k_1$ of 20.2 ±0.21 μM⁻¹s⁻¹ and 23.99 ±1.9 μM⁻¹s⁻¹ and a $k_4$ of 0.067 ±0.0001 μM⁻¹s⁻¹. These values are very close matches to my own.
Table 2. Rates of binding and conformational changes associated with methotrexate binding to the unlabeled *Bs* DHFR and labeled *Bs* DHFR. Based on Dynafit calculation of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. **Data Folders:** U MTX Binding No.NADPH, L MTX Binding No.NADPH. The script files are in the Dynafit Ready Data Files + Scripts folder within each relevant binding folder.

Methotrexate binding to *Bs* DHFR can be modeled as two separate, two step processes. This implies that *Bs* DHFR is a dynamic system. Based on this and previous studies *Bs* DHFR like many enzymes is not rigid and at equilibrium is most often found in two forms (E and E’). The separate conformations of *Bs* DHFR bind methotrexate at different rates and the motions that *Bs* DHFR goes through after ligand binding (E+L→E.L and E’+L→E’L) can conform to a model where *Bs* DHFR undergoes a conformational change after binding takes place (EL→EL’).

<table>
<thead>
<tr>
<th></th>
<th>Average</th>
<th>Standard Error</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unlabeled 0.25s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$k_1$</td>
<td>23.8 $\mu$M$^{-1}$ s$^{-1}$</td>
<td>2.2</td>
</tr>
<tr>
<td>$k_{-1}$</td>
<td>0.8 s$^{-1}$</td>
<td>0.29</td>
</tr>
<tr>
<td>Unlabeled 100s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$k_2$</td>
<td>0.02 s$^{-1}$</td>
<td>0.0027</td>
</tr>
<tr>
<td>$k_{-2}$</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Labeled 100s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$k_4$</td>
<td>0.072 $\mu$M$^{-1}$ s$^{-1}$</td>
<td>0.00013</td>
</tr>
<tr>
<td>$k_{-4}$</td>
<td>0.0064 s$^{-1}$</td>
<td>0.000066</td>
</tr>
</tbody>
</table>
Figure 11: Unlabeled *Bs* DHFR (1 μM) mixed with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (left). Data File: U MTX Binding No.NADPH 100s Data. Data Folder: U MTX Binding No.NADPH. This shows a slow concentration independent fluorescence decrease that can be attributed to the $k_2$ step of rate 0.02 ±0.0027 s$^{-1}$ which is a conformational change. Unlabeled *Bs* DHFR (1 μM) mixed 2.5 μM of MTX in MTEN buffer at pH 7 and at 25.7 °C, control sample was premixed for 5 minutes (right). Data File: U MTX Binding No.NADPH 100s Data +control. Data Folder: U MTX Binding No.NADPH. The control run is mixed together and allowed to bind and settle into its conformations before reading its value providing a constant value with which the conformational change, which can often be subtle, can be more clearly visualized. The right graph zooms in and shows the conformational change.

*NADPH Mixed with *Bs* DHFR* 

Determining how NADPH binds to *Bs* DHFR and what changes in conformation take place is important for clarifying our understanding of the NADPH/MTX/DHFR system. Seeing conformational changes in the DHFR.NADPH complex would suggest
that the conformational equilibrium in DHFR vs. the DHFR.NADPH system are different and should be treated differently.

The binding of NADPH to unlabeled $Bs$ DHFR causes an NADPH concentration dependent increase in tryptophan fluorescence (290 nm) intensity. The traces were fitted to a single step model. This is a fast concentration dependent increase and is over within 0.2 seconds and has a $k_1$ of $19.5 \pm 0.18 \mu M^{-1} s^{-1}$ and a $k_{-1}$ of $3.9 \pm 0.11 s^{-1}$. (Table 3)

**Figure 12:** Unlabeled $Bs$ DHFR (1 μM) mixed with various concentrations of NADPH in MTEN buffer at pH 7 and at 25.2 °C (left). **Data File:** U NADPH Binding 0.25s Data. **Data Folder:** U NADPH Binding. This shows a fast concentration independent fluorescence increase that can be attributed to the $k_1$ step of rate $19.5 \pm 0.18 \mu M^{-1} s^{-1}$.

Labeled $Bs$ DHFR (1 μM) mixed with various concentrations of NADPH in MTEN buffer at pH 7 and at 25.2 °C (right). **Data File:** L NADPH Binding 0.25s Data. **Data Folder:** L NADPH Binding. This shows a fast concentration independent fluorescence decrease that can be attributed a $k_4$ step of rate $35.6 \pm 0.11 \mu M^{-1}s^{-1}$. 
The binding of NADPH to labeled Bs DHFR causes a NADPH concentration dependent decrease in MDCC fluorescence intensity. The traces were fitted to a single step equation. This is a fast concentration dependent decrease is over within 0.25 seconds and has a $k_4$ of $35.6 \pm 0.15 \mu\text{M}^{-1}\text{s}^{-1}$ and a $k_-4$ of near $0 \text{s}^{-1}$. (Table 3)

Longer unlabeled traces showed a small decrease in fluorescence intensity indicating a slow NADPH concentration independent decrease. These longer traces were fit to a two-step model. The fast step is attributed to NADPH binding, $k_1$, and the slower step is attributed to the conformational change, $k_2$. The rate constant $k_2$ was found to be $0.02 \pm 0.0002 \text{s}^{-1}$ and $k_-2$ could not be calculated from the data.

Longer labeled traces showed a small decrease in fluorescence intensity indicating a slow NADPH independent decrease. These longer traces were fit to a single step model of a conformational change. The rate constant $k_-2$ was found to be $0.1 \pm 0.0041 \text{s}^{-1}$ and $k_2$ was unable to be calculated from the data. (Table 3)

NADPH binding to Bs DHFR, like methotrexate, can be modeled with two conformers binding ligand at different rates. It is likely that Bs DHFR existing as two conformers (E and E’) bind NADPH at different rates and the motions that Bs DHFR goes through after ligand binding ($E+L \rightarrow E.L$ and $E’+L \rightarrow E’L$) can conform to a model where Bs DHFR undergoes a conformational change after binding takes place ($E.L \rightarrow EL’$).
Figure 13: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U NADPH Binding 100s Data. Data Folder: U NADPH Binding. This shows a slow concentration independent fluorescence decrease that can be attributed to the \( k_2 \) step of rate 0.02 ±0.0002 s\(^{-1}\) which is a conformational change. Unlabeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in MTEN buffer at pH 7 and at 25.2 °C (right). Data File: L NADPH Binding 100s Data. Data Folder: L NADPH Binding. This shows a concentration independent fluorescence decrease that can be attributed to the \( k_2 \) step of rate 0.01 ±0.0041 s\(^{-1}\) which is a conformational change.
Figure 14: Model with the rates of binding and conformational changes associated with NADPH binding to the unlabeled $B_s$ DHFR and labeled $B_s$ DHFR.

Table 3. Rates of binding and conformational changes associated with methotrexate binding to the unlabeled $B_s$ DHFR and labeled $B_s$ DHFR. Based on Dynafit calculation of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. Data Folders: U NADPH Binding, and L NADPH Binding. The script files are in the Dynafit Ready Data Files + Scripts folder within each relevant binding folder.
Finally determining the differences in binding of ligands like methotrexate bind to the DHFR/NADPH holoenzyme complex can clarify the role of NADPH in Bs DHFR methotrexate binding and the importance of NADPH to the study and analysis of inhibitors. A significant change in binding, conformational equilibrium, and/or dissociation rate would be a clear indication of the importance NADPH being included in the analysis process.

The binding of methotrexate to unlabeled holoenzyme causes a methotrexate concentration dependent decrease in tryptophan fluorescence intensity (Fig. 14 left). The traces were fitted to a single step model. This is a fast concentration dependent increase and is over within 0.25 seconds and has a $k_1$ of $24.7 \pm 1.1 \, \mu M^{-1} \, s^{-1}$ and a $k_{-1}$ of $0.03 \pm 0.4 \, s^{-1}$ (Table 4).

The binding of methotrexate to labeled holoenzyme causes a methotrexate concentration dependent decrease in MDCC fluorescence intensity (Fig. 14 right). The traces were fitted to a single step equation. This is a much slower concentration dependent decrease and is over within 100 seconds and has a $k_4$ of $0.052 \pm 0.024 \, \mu M^{-1} \, s^{-1}$ and a $k_{-4}$ of $0.03 \pm 0.01 \, s^{-1}$ (Table 4).
Figure 15: Unlabeled Bs DHFR (1 μM) premixed with NADPH (5 μM) and then mixed with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (left). Data File: U MTX Binding W.NADPH 0.25s Data. Data Folder: U MTX Binding W.NADPH. This shows a fast concentration dependent fluorescence decrease corresponding to the $k_1$ step of rate $24.7 \pm 1.1 \, \mu M^{-1} \, s^{-1}$. Labeled Bs DHFR (1 μM) premixed with NADPH (5 μM) and then mixed with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (right). Data File: L MTX Binding W.NADPH 100s Data. Data Folder: L MTX Binding W.NADPH This shows a much slower concentration dependent fluorescence decrease corresponding to the $k_4$ step of rate $0.052 \pm 0.024 \, \mu M^{-1} \, s^{-1}$. 
Figure 16: Model for the rates of binding and conformational changes associated with methotrexate binding to the unlabeled DHFR.NADPH complex and labeled DHFR.NADPH complex.

<table>
<thead>
<tr>
<th>Unlabeled 0.25s</th>
<th>Average</th>
<th>Standard Error</th>
</tr>
</thead>
<tbody>
<tr>
<td>$k_1$</td>
<td>$24.7 , \mu M^{-1}s^{-1}$</td>
<td>1.1</td>
</tr>
<tr>
<td>$k_{-1}$</td>
<td>$0.03 , s^{-1}$</td>
<td>0.4</td>
</tr>
<tr>
<td>Unlabeled 100s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$k_2$</td>
<td>$0.054 , s^{-1}$</td>
<td>0.0019</td>
</tr>
<tr>
<td>$k_{-2}$</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Labeled 100s</td>
<td></td>
<td></td>
</tr>
<tr>
<td>$k_4$</td>
<td>$0.052 , \mu M^{-1}s^{-1}$</td>
<td>0.024</td>
</tr>
<tr>
<td>$k_{-4}$</td>
<td>$0.03 , s^{-1}$</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Table 4. Rates of binding and conformational changes associated with methotrexate binding to the unlabeled DHFR.NADPH complex and labeled $B$ DHFR.NADPH complex. Based on Dynafit calculation of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. Data Folders: U MTX Binding W.NADPH, L MTX Binding W.NADPH. The script files are in the Dynafit Ready Data Files + Scripts folder within each relevant binding folder.
Dissociation rates of methotrexate from Bs DHFR and the DHFR.NADPH complex

Determining the differences in the dissociation of ligands like methotrexate from *Bs* DHFR and the DHFR.NADPH complex can clarify the role of NADPH in *Bs* DHFR methotrexate binding and the importance of NADPH to the study and analysis of inhibitors. A significant change in dissociation, indicates an importance of the cofactor in not just activating the enzyme but preventing ligands from dissociating.

The dissociation of methotrexate from unlabeled *Bs* DHFR causes a decrease in tryptophan fluorescence intensity (Fig. 16 left). The rates were calculated an exponential decay model. This shows a fluorescence decrease corresponding to the dissociation rate of $0.015 \text{ s}^{-1} \pm 0.007965$.

The dissociation of methotrexate from labeled *Bs* DHFR causes an increase in tryptophan fluorescence intensity (Fig. 16 right). The rates were calculated an exponential rise model. This shows a fluorescence increase corresponding to the dissociation rate of $0.02 \text{ s}^{-1} \pm 0.0000921$. 
**Figure 17**: Unlabeled *Bs* DHFR (1 μM) premixed with methotrexate (5 μM) mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (left). **Data File**: U MTX Dissociation No NADPH Data. **Data Folder**: U MTX Dissociation No.NADPH. This shows a fluorescence decrease corresponding to the dissociation rate of 0.015 s⁻¹ ±0.007965. Labeled *Bs* DHFR (1 μM) premixed with methotrexate (5 μM) and then mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (right). **Data File**: L MTX Dissociation No NADPH Data. **Data Folder**: L MTX Dissociation No.NADPH. This shows a fluorescence increase corresponding to the dissociation rate of 0.02 s⁻¹ ±0.0000921.

The dissociation of methotrexate from the unlabeled DHFR.NADPH complex causes a decrease in tryptophan fluorescence intensity (Fig. 17 left). The rates were calculated an exponential decay model. This shows a fluorescence decrease corresponding to the dissociation rate of 2.87e⁻⁵ s⁻¹ ±0.82 e⁻⁵.
Figure 18: Unlabeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U MTX Dissociation With NADPH Data. Data Folder: U MTX Dissociation W.NADPH. This shows a fluorescence decrease corresponding to the dissociation rate of $2.87 \times 10^{-5}$ s$^{-1} \pm 0.82 \times 10^{-5}$. Labeled Bs DHFR (1 μM) premixed with methotrexate (5 μM), and NADPH (5 μM), and then mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (right). Data File: Labeled MTX Dissociation With NADPH Data. Data Folder: L MTX Dissociation W.NADPH. This shows a fluorescence increase corresponding to the dissociation rate of $2.1 \times 10^{-5}$ s$^{-1} \pm 0.271 \times 10^{-5}$. This specific dissociation curve for the labeled enzyme had irregularities that appeared in the control experiment (run 48 hours without NADPH) The control was used in file L MTX Dissociation W.NADPH and was subtracted from the average dissociation curve to correct for the irregularities.

The dissociation of methotrexate from the labeled DHFR NADPH complex causes an increase in tryptophan fluorescence intensity (Fig. 17 right). The rates were
calculated an exponential rise model. This shows a fluorescence increase corresponding to the dissociation rate of $2.1 \times 10^{-5} \text{ s}^{-1} \pm 0.271 \times 10^{-5}$.

*Discussion*

Previously determined experimental results were verified by our experiments and the kinetic data is consistent with previously determined models for methotrexate binding. We confirmed that *Bs* DHFR exists in two distinct configurations E and E’ at a ratio of 0.7:0.3. We have extended scope of the model to include the cofactor NADPH binding resulting in a ENADPH and E’NADPH ratio of 0.6:0.4. This multistep model is supported by the distinct NADPH and methotrexate binding rates calculated from tryptophan fluorescence and the MDCC fluorophore fluorescence. Furthermore, the model is valid when methotrexate binding to the holoenzyme is determined following NADPH bindings.

The difference in rate of methotrexate binding between the apoenzyme and the holoenzyme is indicative of the importance of the cofactor. However, the most significant change from the binding of *Bs* DHFR to NADPH is that the dissociation rate of methotrexate from the bound complex is reduced. This shift results in an increase in stability. This makes sense from a biological perspective as it ensures that when all components are present in solution that they not only bind to each other at an appropriate speed but also that they remain bound so that they achieve an appropriate reaction rate. The scale of the shift in dissociation rate is very interesting. The dissociation rate of the *Bs* DHFR without cofactor is fast while with cofactor it is 1000 times slower, a drastic decrease (Fig. 18).
Figure 19: Labeled methotrexate dissociation without NADPH (Fig. 16 right) compared to with NADPH (Fig. 17 right). Here we can clearly visualize the difference in timescale caused by NADPH. When there is no NADPH the timescale for dissociation is 600 seconds with a rate of $0.02 \text{ s}^{-1} \pm 0.0000921$ and when there is NADPH the timescale for dissociation is 48 hours with a rate of $2.1 \times 10^5 \text{ s}^{-1} \pm 0.271 \times 10^5$.

We can conclude that important information regarding the kinetics of enzymes and of $Bs$ DHFR in particular are missing if the analysis of inhibitor binding data is preformed while a key cofactor is missing. This is especially true when analyzing pharmaceuticals. For example, a cell with high energy (high NADPH concentration) would remain inhibited by methotrexate for much longer than a cell with low energy. This difference could alter effectiveness and toxicity so should be carefully analyzed.
References


43. Silva D.A., Bowman G., Sosa-Peinado A., Huang X., (2011) A Role for Both Conformational Selection and Induced Fit in Ligand Binding by the LAO Protein. Public Library of Science Computational Biology. 7 e1002054
Appendix

\[
\text{Absorbance} = \frac{\text{Extinction coefficient (M}^{-1}\text{cm}^{-1}) \times \text{Path length (cm)}}{\text{Concentration (M)}}
\]

\[
\text{Absorbance L Enzyme (419 nm)} = \frac{\text{Ext. coeff, (50000M}^{-1}\text{cm}^{-1}) \times \text{Path length (0.1cm)}}{\text{Concentration L Enzyme(M)}}
\]

\[
\text{Concentration L Enzyme(M)} \times \text{Ext. coeff, (10000M}^{-1}\text{cm}^{-1}) \times \text{Path length (0.1cm)} = \text{Absorbance L Enzyme (280 nm)}
\]

\[
\text{Absorbance Total Enzyme (280 nm)} - \text{Absorbance L Enzyme (280 nm)} = \text{Absorbance U Enzyme (280 nm)}
\]

\[
\text{Absorbance U Enzyme (280 nm)} = \frac{\text{Ext. coeff, (25565M}^{-1}\text{cm}^{-1}) \times \text{Path length (0.1cm)}}{\text{Concentration U Enzyme(M)}}
\]

\[
\frac{\text{Concentration L Enzyme(M)}}{\text{Concentration U Enzyme(M)} + \text{Concentration L Enzyme(M)}} = \text{Labeling Efficiency}
\]

**Figure 20:** Equation for converting absorbance to concentration and for measuring labeling efficiency. Absorbance of labeled enzyme at 419 nm and of total enzyme at 280 nm are the measured values for calculating labeling efficiency.
<table>
<thead>
<tr>
<th>A280</th>
<th>=</th>
<th>ext. coeff</th>
<th>C (M)</th>
<th>l cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.14</td>
<td>25565</td>
<td>5.47624E-05</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>54.76237043</td>
<td>uM</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.00125</td>
<td>L</td>
<td>0.068452963</td>
<td>umol</td>
</tr>
</tbody>
</table>

**Label**

<table>
<thead>
<tr>
<th>mg/ml</th>
<th>mg/mmol</th>
<th>umol/ul</th>
<th>ul</th>
<th>0.068452963</th>
<th>umol enzyme</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.22</td>
<td>383.4</td>
<td>0.000573813</td>
<td>357.8845367</td>
<td>0.205358889</td>
<td>umol label</td>
</tr>
</tbody>
</table>

**Labeling**

<table>
<thead>
<tr>
<th>A419 L</th>
<th>=</th>
<th>ext. coeff</th>
<th>C (M)</th>
<th>l cm</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.189</td>
<td>50000</td>
<td>0.0000378</td>
<td>0.1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>37.8</td>
<td>uM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A280 E = A280 L - A280 L

<table>
<thead>
<tr>
<th>A280</th>
<th>=0.135</th>
<th>0.0972</th>
<th>25565</th>
<th>3.80207E-05</th>
<th>0.1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>38.02073147</td>
<td>uM</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A280 L

<table>
<thead>
<tr>
<th>0.0378</th>
<th>10000</th>
<th>0.0000378</th>
<th>0.1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>37.8</td>
<td>uM</td>
<td></td>
</tr>
</tbody>
</table>

0.994194444 labeling efficiency

**Figure 21:** Sample calculation sheet of absorbance, needed label concentration, and labeling efficiency using the equations laid out in Fig. 19. **File:** Absorbance Calculation (In the base data folder). Bold values are measured values and the file auto calculates everything else.
Inventory

Box 1 DHFR supplies

A. 2x 0.5mL tube MTX 35.4mM
B. 1x 1.5mL tube MTX 1000uM
C. 1x 1.5mL tube NADPH 1000uM
D. 1x 0.5mL tube TMP 365mM
E. 1x 1.5mL tubes of labeled enzyme
F. 4x 0.5mL tubes of Labeled enzyme 47.29uM
G. 1x 1.5mL tube of transformed *E. coli* cell culture C73A, S131C
H. 3x1.5mL tubes of unlabeled enzyme
I. 1x 1.5mL tube MDCC old Stock
J. 2x 0.5mL tube of MDCC at 0.22mg/mL
K. 4x 0.5mL tube of unknown (variable) concentration of MDCC (contain particulate)

(box #2 was combined into box 1)
**Box #3 DHFR pellets**

A. 2x Falcon tubes each contain a cell pellet
B. 1x 10 mL tube with DHFR

**Box 4 Maryam Legacy box**

A. Old Pellets from 2012
B. 1x 1.5mL tube of transformed *E. coli* cell culture C73A, S131C
Box 1, 3, 4 in the stand

The stand (A) in the Freezer